Objectives: To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone.Design and setting: A 52 week, two period, double blind, multicentre trial during which patients whose symptoms remained uncontrolled by inhaled corticosteroids were randomised to add montelukast or salmeterol.Participants: Patients (15-72 years; n = 1490) had a clinical history of chronic asthma for >= 1 year, a baseline forced expiratory volume in one second (FEV1) value 50-90% predicted, and a ? agonist improvement of >= 12% in FEV1.Main outcome measures: The primary end point was the percentage of patients with at least one ast...
SummaryObjectivesThis multicentre, parallel group, double-blind, double-dummy, randomised 24-week st...
SummaryObjectiveThe aim of this study was to assess asthma control using salmeterol plus fluticasone...
SummaryBackgroundWe evaluated the dose–response of umeclidinium (UMEC; a long-acting muscarinic anta...
Objectives To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propio...
Background: Rhinopolyposis is considered to be a non-immunoglobulin E-mediated inflammatory conditio...
Background: Few studies have compared treatment strategies in patients with asthma poorly controlle...
Asthma patients who continue to experience symptoms despite taking regular inhaled corticosteroids r...
BACKGROUND: Few studies have compared treatment strategies in patients with asthma poorly controlled...
Objective: The Asthma Salford Lung Study demonstrated the effectiveness of initiating once-daily flu...
AbstractThe aim of this study was to compare the efficacy and safety of salmeterol/fluticasone propi...
BackgroundThe combination of fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), and vil...
AbstractThis study was designed to determine whether the benefit of adding salmeterol was superior t...
AbstractAsthma patients who continue to experience symptoms despite taking regular inhaled corticost...
ABSTRACT. Background. Guidelines recommend daily controller therapy for mild persistent asthma. Mon-...
would be considered at least as effective as fluticasone if the treatment differ-ence (average perce...
SummaryObjectivesThis multicentre, parallel group, double-blind, double-dummy, randomised 24-week st...
SummaryObjectiveThe aim of this study was to assess asthma control using salmeterol plus fluticasone...
SummaryBackgroundWe evaluated the dose–response of umeclidinium (UMEC; a long-acting muscarinic anta...
Objectives To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propio...
Background: Rhinopolyposis is considered to be a non-immunoglobulin E-mediated inflammatory conditio...
Background: Few studies have compared treatment strategies in patients with asthma poorly controlle...
Asthma patients who continue to experience symptoms despite taking regular inhaled corticosteroids r...
BACKGROUND: Few studies have compared treatment strategies in patients with asthma poorly controlled...
Objective: The Asthma Salford Lung Study demonstrated the effectiveness of initiating once-daily flu...
AbstractThe aim of this study was to compare the efficacy and safety of salmeterol/fluticasone propi...
BackgroundThe combination of fluticasone furoate (FF), a novel inhaled corticosteroid (ICS), and vil...
AbstractThis study was designed to determine whether the benefit of adding salmeterol was superior t...
AbstractAsthma patients who continue to experience symptoms despite taking regular inhaled corticost...
ABSTRACT. Background. Guidelines recommend daily controller therapy for mild persistent asthma. Mon-...
would be considered at least as effective as fluticasone if the treatment differ-ence (average perce...
SummaryObjectivesThis multicentre, parallel group, double-blind, double-dummy, randomised 24-week st...
SummaryObjectiveThe aim of this study was to assess asthma control using salmeterol plus fluticasone...
SummaryBackgroundWe evaluated the dose–response of umeclidinium (UMEC; a long-acting muscarinic anta...